Impact of multidrug resistance 1 gene polymorphism on tacrolimus dose and concentration-to-dose ratio in Chinese liver transplantation recipients

Chinese Journal of Medical Genetics

Volumn 22, Issue 6, 2005, Pages 616-620

  Jin, Jing ^a   Wu, Li Hua ^a   Wang, Wei Lin ^a   Yu, Song Feng ^a   Yan, Sheng ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gene polymorphism; Liver transplantation; Multidrug resistance 1 gene; Tacrolimus

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ALLELE; ARTICLE; BODY WEIGHT; CHINESE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA POLYMORPHISM; DONOR; FEMALE; GENE; GENOTYPE; HUMAN; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 29244457552     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. MacPhee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation, 2002, 74:1486-1489.
2. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of P4503A and P-glycoprotein. Clin Pharmacokinet, 2001, 40:159-168.
3. Haufroid V, Mourad M, van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics, 2004, 14:147-154.
4. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 2000, 97:3473-3478.
5. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol, 2003, 43:285-307.
6. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics, 2003, 4:397-410.
7. Zheng H, Zeevi A, Schuetz E, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol, 2004, 44:135-140.
8. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYF3A4, CYP3A5, MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003, 74:245-254.
9. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol, 2003, 14:1889-1896.
10. Haehner BD, Goiski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P4503A activity in humans. Mol Pharmacol, 1996, 50:52-59.
11. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit, 2004, 26:180-185.